BioSpace News Archive

MedGene Therapeutics, Inc. (MedGene), a biopharmaceutical company dedicated to bringing adoptive cell therapies to solid tumors, today announced the publication of a peer-reviewed article titled “Krüppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells” (https://www.science.org/doi/epdf/10.1126/sciadv.adc9346).

Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses has released the Company’s unaudited 3Q2022 condensed interim consolidated Financial Statements.

Eisai Co., Ltd. and Biogen Inc. announced that the results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed presence of amyloid pathology in the brain, were presented at the 2022 Clinical Trials on Alzheimer’s Disease conference, in San Francisco, California and virtually.

Cipla Limited and its wholly owned subsidiary Cipla USA Inc., announced the launch of Leuprolide Acetate Injection Depot 22.5mg.

The Alzheimer’s Association welcomes and is further encouraged by the full Phase 3 data presented by Eisai and Biogen from the CLARITY AD global Phase 3 clinical trial of lecanemab.

BioArctic AB’s partner Eisai announced that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world’s most prestigious peer-reviewed medical journals.

Freeline Therapeutics Holdings plc announced that it received approval from the Nasdaq Stock Market LLC to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.

Based on study results presented at the 15th Clinical Trials on Alzheimer’s Disease conference and published in The New England Journal of Medicine, amyloid-clearing drug lecanemab—poised for FDA approval early next year—will be a positive step in the treatment of Alzheimer’s.

RaySearch announces a partnership with Leo Cancer Care in Great Britain for the development of a streamlined treatment planning solution for upright treatments.